Abstract. In this study, we demonstrate an important role of activation of the hypoxia-inducible factor-1 (HIF-1) pathway in endometrial carcinogenesis and tumor phenotype development of endometrial carcinoma, and suggest a unique role of the HIF-1-target gene, differentiated embryo chondrocyte 2 (DEC2), in carcinogenesis. Hypoxia caused an increase in HIF-1· protein expression in 4 endometrial carcinoma cell lines. The expressions of its 5 target genes -DEC1, DEC2, carbonic anhydrase-9 (CA9), vascular endothelial growth factor (VEGF), and solute carrier family 2, member 1 (SLC2A1) -also reactively increased in most of the cell lines, except for DEC2 in the SNG-M cells. The expression levels of DEC2, CA9, and SLC2A1 were significantly higher in the 4 atypical hyperplasia tissues and 82 endometrial carcinomas compared with those in the 21 normal endometria. Clinicopathological analyses of carcinoma patients revealed a significant correlation of the VEGF and SLC2A1 expression with the status of lymph-vascular involvement and lymph node metastasis. The expression levels of CA9 and VEGF were significantly higher in the tumors of post-as opposed to pre-menopausal patients. The SLC2A1 expression was also related to the FIGO stage, but the DEC2 expression was inversely related to the FIGO grade. The activation of the HIF-1 pathway could be related to endometrial carcinogenesis, and the component, DEC2, could have different expression-regulatory mechanisms and unique roles in carcinogenesis.
Introduction
Endometrial carcinoma is one of the most common gynecological malignancies in the world (1) (2) (3) . Even though the overall 5-year survivals for all the stages are ~80%, many women die from the cancer each year, and existing screening and therapeutic modalities are unlikely to substantially decrease mortality. These unsatisfactory conditions have promoted research for novel biomarkers and targets for the prevention and/or therapy of this carcinoma, and the factors involved in cellular hypoxic reaction are increasingly highlighted as possible candidates.
Tissue hypoxia is now known to contribute to biologically aggressive tumor phenotypes and the emergence of therapeutic resistance (4) (5) (6) (7) (8) . In solid tumors, including endometrial carcinomas, cancer cells are often exposed to low oxygen tension (hypoxia), low pH, and low nutrition due to inadequate vasculature, which cause a variety of biological changes through the alterations of various gene expressions (5) (6) (7) . Hypoxia-inducible factor-1· (HIF-1·) is a key transcription factor regulating a variety of hypoxia-inducible genes: The protein rapidly degrades in the cells under normoxic conditions but is strikingly induced by hypoxia (4) (5) (6) (7) . Hypoxic stabilization of the HIF-1· protein leads to the multiple-step activation of the HIF-1· function involving its nuclear translocation and heterodimerization with HIF-1ß [also called aryl hydrocarbon receptor nuclear translocator (ARNT)] to form transcription factor HIF-1. HIF-1 then interacts with the cognate hypoxia-response elements (HRE) of target promoters, followed by the recruitment of transcriptional coactivators (4) (5) (6) (7) . To date, dozens of HIF-1-target genes have been identified, and their functional significances have been analyzed in a variety of cancers (5) (6) (7) .
Previously, we found the functional HRE in the promoter region of the differentiated embryo chondrocyte 1 (DEC1)/ BHLHB2 and DEC2/BHLHB3 genes which identified them as HIF-1-target genes (9) . The DEC1 coding basic helixloop-helix (bHLH) transcription factor was originally identified as the molecule expressed in cAMP-dependently differentiated embryo chondrocytes (10) , and DEC2 was cloned from the human DNA database of EST as a member of the DEC subfamily (11) . Several reports have suggested that DEC subfamily proteins could play a role in tissue development and regulation of the circadian rhythm at the transcriptional level (9) (10) (11) (12) (13) (14) (15) . Several hypoxia-inducible genes, including carbonic anhydrase-9 (CA9), vascular endothelial growth factor (VEGF), and solute carrier family 2, member 1 (SLC2A1), have been well-characterized in various cancer tissues. However, little is known about DECs in cancer tissues, and almost nothing about DEC2 (16) (17) (18) (19) (20) (21) (22) (23) .
In this study, we evaluated the expression of DEC1 and DEC2, along with the well-known hypoxia-inducible genes CA9, VEGF, and SLC2A1 in endometrial carcinoma, complex atypical endometrial hyperplasia, and adjacent normal endometria, in order to clarify the clinical significance of DECs in carcinogenesis in anticipation of their being novel biomarkers or targets for the prevention and/or therapy of endometrial carcinomas.
Materials and methods
Chemicals. All chemicals were of analytical grade and were purchased from Wako Pure Chemicals (Osaka, Japan) and Sigma (St. Louis, MO, USA).
Cell culture. A cervical carcinoma cell line, HeLa, and three endometrial carcinoma cell lines, HEC-1, SNG-II, and SNG-M, were obtained from the Health Science Research Resources Bank (Osaka, Japan). The Ishikawa (3-H-12 No. 117) cell line was kindly provided by Dr M. Nishida (Tsukuba University, Japan) (24) . The cell lines were maintained in Eagle's minimal essential medium (MEM; Sigma-Aldrich Japan, Tokyo, Japan) or Dulbecco's MEM (DMEM; Sigma) supplemented with 10% fetal bovine serum (FBS; BioWhittaker, Verviers, Belgium) plus penicillin (50 IU/ml) and streptomycin (50 μg/ml) with passage every 3 days. The cells were incubated for 12-24 h under normoxic (21% pO 2 ) or hypoxic (1% pO 2 ) conditions prior to analysis. The cells were collected after washing with PBS and the cell pellets were immediately frozen in liquid nitrogen and stored at -80˚C until use. -
were prepared from frozen cell pellets or tissue specimens using the RNeasy ® mini kit (Qiagen) according to the manufacturer's instructions, and stored at -80˚C until use. All RNA samples were qualified using Agilent Technologies 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA). Total RNA (2 μg) was reverse-transcribed using the High-Capacity cDNA Archive™ kit (Applied Biosystems, Foster City, CA, USA) with random primers according to the manufacturer's instructions. The two hundredth aliquot of the cDNA (equivalent to 10 ng total RNA) was subjected to real-time RT-PCR. Realtime PCR was performed using TaqMan Gene Expression Assay (Applied Biosystems). Each reaction was carried out in triplicate for all the cell lines and tissues, using the ABI Prism 7900HT sequence detection system (Applied Biosystems). These triplicate measurements were averaged, and the relative gene expression levels were calculated as the ratio to the expression level of ACTB (ß-actin). A cDNA mix, consisting of 17 various cell lines, was used to create a standard curve of gene expressions.
Immunoblot analysis. After incubation in a 10-cm diameter dish, the cells were collected by scraping, washed with cold-PBS, and the cell pellets were stored at -80˚C until use. Whole cell extracts were prepared by sonication with the lysis buffer (7 M Urea, 10 mM Tris-HCl pH 6.8, 10% Glycerol) supplemented with 1x Complete mini ® protease inhibitor cocktail, 1 mM DTT, and 1 mM PMSF. Fifty micrograms of extracts were subjected to 7% SDS-PAGE and blotted onto nitrocellulose filters. Anti-HIF-1· (BD Biosciences, San Jones, CA, USA) or anti-ß-actin (Sigma) antibody was used as the primary antibody, diluted 1:500 or 1:5000 in TBS containing 0.1% Tween-20 (TBS-T) and 1% non-fat milk at room temperature for 1 h. After several washes, a 1:1000 dilution of anti-mouse IgG horseradish peroxidase conjugate (Amersham Life Science) was used as the secondary antibody and incubated for 1 h at room temperature. After extensive washing with TBS-T buffer, immunocomplexes were visualized using the enhanced chemiluminescence reagent, ECL Plus (NEN Life ScienceProduct, Inc., Boston, MA, USA).
Immunohistochemical staining. Immunohistochemical staining was performed on formalin-fixed, paraffinembedded tissues. For HIF-1· staining, 1:500 diluted anti-HIF-1· mouse monoclonal antibodies (H1·67, Novus Biologicals, Littleton, CO, USA) and the CSA system (Dako, Carpinteria, CA, USA), were employed. The sections were initially immersed in Target Retrieval Solution (Dako) at 97˚C for 45 min, and subsequent steps were performed according to the manufacturer's instructions.
The expression of the HIF-1· protein was defined as positive if distinct nuclear and/or cytoplasmic staining was observed in normal and/or tumor cells in any optical field (Fig. 2) . Stained intensity was compared between the normal and cancer cells.
Statistics. All statistical tests were performed using StatView ® version 5.0 software (SAS Institute Inc., Cary, NC, USA), and the Student's t-test or Mann-Whitney U test were used to determine the P-value.
Results

Hypoxic induction of HIF-1· protein in vitro.
In order to clarify whether a hypoxic signaling pathway was active in the endometrial carcinoma cells, the protein levels of HIF-1· were evaluated under normoxic or hypoxic conditions in 4 human endometrial carcinoma cell lines (Fig. 1A) . After incubation under normoxic (21% pO 2 ) or hypoxic (1% pO 2 ) conditions for 12 h, the cells were harvested and whole cell extracts were prepared. HeLa, a cervical carcinoma cell line, was used as the positive control for HIF-1· induction (25) . Immunoblot analysis showed that hypoxia caused an increase in HIF-1· protein expression in endometrial carcinoma cell lines, although the reaction to hypoxia significantly varied among the cell lines. Compared with the control HeLa cells, HIF-1· induction was greater in the Ishikawa cells, less in the SNG-M and HEC-1 cells, and least in the SNG-II cells. The expression of the HIF-1· protein was barely detected in the hypoxic SNG-II cells, although there was a slight increase compared to its expression in the normoxic cells.
Hypoxic inductions of DEC1, DEC2 and known hypoxiainducible genes in endometrial carcinoma cell lines.
The downstream activity of the HIF-1 signaling pathway after hypoxic treatment was investigated by expression analyses of the target genes, including DEC1 and DEC2. The cells were incubated under the same hypoxic conditions used for the HIF-1· protein analyses, and then total RNAs were extracted from the cell pellets. Real-time RT-PCR analyses revealed that all of the 5 HIF-1 target genes responded to hypoxia in at least some of the cell lines (Fig. 1B) . Hypoxic treatment significantly increased the expression of DEC1, VEGF, and SLC2A1 in all endometrial carcinoma cell lines, as it did in HeLa (P<0.001), and with the exception of the SNG-M cells, the CA9 expression was also increased in 4 of the 5 cell lines (P<0.001). However, the reaction of DEC2 to hypoxia varied among the cell lines: Hypoxic treatment significantly increased the expression of DEC2 in both the Ishikawa and HEC-1 cell lines (P<0.001), although it did not affect the expression in the SNG-II cells and further reduced it in the SNG-M cells (P<0.001).
Expression of HIF-1· protein in endometrial carcinoma
tissues. In order to clarify whether the HIF-1· signaling pathway was active in the tumor tissues, we then performed immunohistochemical analyses for the HIF-1· protein using tissue sections obtained from 37 endometrial carcinoma patients: In 32 of the 37 tissues (85%), immunoreactivity for the HIF-1· protein was detected in both the normal and carcinoma cells. We found that there were certain differences in reactivity between the carcinoma and normal stromal cells, suggesting the specific role of HIF-1· in carcinoma cells (Table II) . In 27 tissue sections, the staining intensity of the carcinoma cells was stronger than that of normal stromal cells, and the positive stain was observed in both the cytoplasm and nucleus of carcinoma cells (Fig. 2) . However, in normal stromal cells, the protein was mainly stained in the nucleus. After incubation under normoxic (21% pO 2 ) or hypoxic (1% pO 2 ) conditions for 12 h, the cells were harvested and whole cell extracts were prepared. HeLa, a cervical carcinoma cell line, was used as a positive control for the HIF-1· induction. (B) The hypoxic inductions of DEC1 and DEC2, as well as known hypoxia-inducible gene expressions. The cancer cell lines were incubated under the same hypoxic conditions as above, and then total RNAs were extracted from the cell pellets. Real-time RT-PCR analyses of 5 HIF-1 target genes were performed, and the relative gene expression levels were calculated as the ratio to the expression level of ACTB (ß-actin). A cDNA mix, consisting of 17 various cell lines, was used to create standard curve of gene expression. Each value represents the mean ± SD for at least three independent experiments. The P-values were calculated using the Student's t-test.
Expressions of hypoxia-inducible genes in normal
* P<0.001.
We then analyzed the expressions of 5 HIF-1 target genes, DEC1, DEC2, CA9, VEGF, and SLC2A1, in endometrial carcinomas, atypical hyperplasias, and adjacent normal endometria, in order to clarify the significance of these genes in carcinogenesis (Fig. 3) 
------------------------------------------------HIF-1· expression status ------------------------------------------------
The expressions of the HIF-1· protein in endometrial carcinoma tissues. Representative examples of positive and negative staining for the HIF-1· protein were taken at x100 or x400 magnification. Immunoreactivity to HIF-1· was observed in the cytoplasm and nucleus of the cancer cells.
lines, except for DEC2 in the SNG-M cells. We found that the expressions of DEC2, CA9, and SLC2A1 were higher in complex atypical endometrial hyperplasia and endometrial carcinoma tissues compared with those in normal endometria. Furthermore, although the immunolabeling index of the HIF-1· protein in the carcinoma tissues did not correlate with any clinicopathological features of the tumors, the expression of 2 HIF-1 target genes correlated with aggressive clinicopathological features in 82 endometrial carcinomas: VEGF and/or SLC2A1 correlated with lymphatic involvement, lymph-node metastasis, and the FIGO stage, and CA9 and VEGF, correlated with the menopausal status, suggesting the existence of cross-talk between hypoxia-and estrogensignaling. Since the expressions of several HIF-1-target genes increased in the process of endometrial carcinogenesis and were related to clinicopathological characteristics, it is likely that the activation of the HIF-1 pathway could play a key role in carcinogenesis and tumor phenotype development in endometrial carcinoma. However, only DEC2 inversely correlated with the FIGO grade in its expression level. DEC2 is involved in tissue development and regulation of the circadian rhythm as a transcriptional repressor (11, 14, 15) , although its specific function in cancer remains to be clarified. Several reports have commented on the role of the other HIF-1 target genes including DEC1 in various cancers (16) (17) (18) (19) , and GLUT1 (SLC2A1 product) in endometrioid adenocarcinomas (23) . However, ours is the first report to analyze the roles of DEC2 in endometrial carcinoma. Our data suggest that DEC2 can act on carcinogenesis and tumor phenotype development independently of the other HIF-1 target genes including, DEC1. It should be noted that, among the various genes, differences between DEC1 and DEC2 were noticeable: Contrary to the unchanged DEC1 expression, DEC2 increased its expression levels in atypical hyperplasia or endometrial carcinoma compared to normal endometria, suggesting an association with carcinogenesis. The DEC1 protein expression analyses in lung or breast cancers (16) (17) (18) , revealed an augmented expression in breast cancers. Although the DEC1 protein expression was observed in 38% in a series of 115 non-small cell lung carcinomas, DEC1 was persistently expressed in normal bronchial and alveolar tissues, suggesting that the loss of DEC1 expression could be an early event in the development of lung cancer (19) . Furthermore, it has been demonstrated that the DEC1/2 distribution in the organs is different (11) . Despite some inconsistent data, the overall reactivity of DEC2 to hypoxia correlated with that of the HIF-1· protein in vitro, possibly suggesting its distinctive nature, i.e., HIF-1-dependent induction. Although DEC2 promotes carcinogenesis, as opposed to DEC1 in lung cancers, their functions in carcinomas could be origin-or cell type-specific and thereby discrete. The DEC2 expression in cancer cell lines could be determined by certain DEC2-targeting mechanisms that occur during carcinogenesis. Despite an incomplete under- standing of their functions as transcription repressors, findings that the expression of DEC2 was stable in SNG-II, and further decreased in SNG-M under hypoxic conditions, could be explained by mutation(s) of the promoter region or the over-expression of transcriptional repressors such as DEC1 (14) . We encountered unexpected data in our study: The activation of the HIF-1 downstream gene did not always correlate with the HIF-1· protein levels in vitro, and the immunolabeling index of the HIF-1· protein in carcinoma tissues did not correlate with any clinicopathological features of the tumors, contrary to the findings with the activated HIF-1 downstream genes in vivo. One hypothesis is that the HIF-1 pathway can be activated not only by hypoxia but also by the inactivation of several tumor suppressor genes such as VHL, TP53 and PTEN, as reported elsewhere (5) (6) (7) (26) (27) (28) . Since mutations of TP53 and PTEN were commonly observed in endometrial carcinomas, the inactivation of these tumor suppressor genes could be one of the mechanisms that activated the HIF-1 pathway in endometrial carcinogenesis (2, 3) . Our immnohistochemical analysis supported this hypothesis, since we found only nuclear staining in some adjacent stromal tissues, but both nuclear and cytoplasmic strong staining in the cancer cells, suggesting the aberrant activation of HIF-1· in cancer cells. The poor correlation in the activation between HIF-1· and its downstream genes could also be due to the involvement of the recruitment of coactivators and/or other transcription factors, including HIF-2·, among the mechanisms. Even so, the detailed mechanisms in the HIF-1 pathway activation and subsequently ONCOLOGY REPORTS 17: 871-878, 2007 Table III. Statistical analysis of the clinicopathological characteristics relative to gene expression levels in endometrial carcinomas. 
-----------------------------------------------------------------------------------------------------
t, Student's t-test; U, Mann-Whitney U test. Bold text, statistically significant.
in the carcinogenesis of endometrial carcinoma, as well as the functional roles of the HIF-1 downstream genes, remain unclear as with other cancers. Further investigation is required.
In conclusion, we demonstrated the increased expression of several hypoxia-inducible genes, including the previously unreported DEC2 in endometrial carcinogenesis. The activation of the HIF-1 pathway played a part in carcinogenesis and tumor phenotype development in endometrial carcinoma. Among the HIF-1-target genes, the DEC2 expression can be differentially regulated and plays a unique role in endometrial carcinogenesis.
